AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20100135 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 48
Study 19192440 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (10-50 mg/day)
Number of subjects: 70
Study 19192440 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (2.5-12.5 mg/day)
Number of subjects: 70
Study 17956027 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiggle foam pack
Number of subjects: 20
Study 17956027 — intervention group
Group type: COMPARATOR
Intervention: Merocel foam pack
Number of subjects: 20
Study 15088527 — intervention group
Group type: EXPERIMENTAL
Intervention: Karinat (2.5 mg beta-carotene, 5 mg alpha-tocopherol, 30 mg ascorbic acid, 150 mg garlic powder, one tablet twice a day for 6 months)
Number of subjects: 66
Study 15088527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet twice a day for 6 months)
Number of subjects: 66
Study 10698231 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (titrated oral dosage)
Number of subjects: 42
Study 10698231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9339507 — intervention group
Group type: EXPERIMENTAL
Intervention: WALLGRAFT Endoprosthesis
Number of subjects: 10
Study 9339507 — intervention group
Group type: COMPARATOR
Intervention: WALLSTENT Endoprosthesis
Number of subjects: 10
Study 8232766 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (10 mg/kg, p.o. at 8.00 h)
Number of subjects: 15
Study 8232766 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15
Study 3937403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial prophylaxis with metronidazole and gentamicin
Number of subjects: 0
Study 3937403 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone
Number of subjects: 0
Study 30522822 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery programme for ICU survivors
Number of subjects: 181
Study 30522822 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 181
Study 28161697 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction to a target of 120 mm Hg
Number of subjects: 0
Study 28161697 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure management (not specified)
Number of subjects: 0
Study 25850966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, intravenous)
Number of subjects: 66
Study 25850966 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 66
Study 22721608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (150mg)
Number of subjects: 28
Study 22721608 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol gel (2mg)
Number of subjects: 28
Study 22721608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20623305 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive rehabilitation (S)
Number of subjects: 49
Study 20623305 — intervention group
Group type: COMPARATOR
Intervention: Experimental preventive rehabilitation (E)
Number of subjects: 49
Study 19167999 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (specific types not mentioned)
Number of subjects: 0
Study 19167999 — intervention group
Group type: EXPERIMENTAL
Intervention: d-ROMs test
Number of subjects: 0
Study 19167999 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant hierarchy
Number of subjects: 0
Study 19167999 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosages of single antioxidants
Number of subjects: 0
Study 16966852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (group P)
Number of subjects: 50
Study 16966852 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (group NP)
Number of subjects: 50
Study 14758376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin drops intraoperatively
Number of subjects: 150
Study 14758376 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day postoperative course of ciprofloxacin drops
Number of subjects: 150
Study 14758376 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic drops (control group)
Number of subjects: 150
Study 14758376 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin drops (group 2)
Number of subjects: 150
Study 11251353 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy with coronary angiography and revascularization procedures within 7 days after admission
Number of subjects: 0
Study 11251353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin treatment
Number of subjects: 0
Study 11251353 — intervention group
Group type: COMPARATOR
Intervention: Continuation with dalteparin therapy after revascularization procedures
Number of subjects: 0
Study 9489063 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (25‐150 mg daily)
Number of subjects: 101
Study 9489063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin (75‐150 mg daily)
Number of subjects: 101
Study 9489063 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 101
Study 9489063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 101
Study 7871037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (FAST condition) - 20 mg single dose
Number of subjects: 9
Study 7871037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (SLOW condition) - 6 doses of 4 mg administered at 30-min intervals
Number of subjects: 9
Study 7871037 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 9
Study 7871037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (FAST condition)
Number of subjects: 9
Study 7871037 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (SLOW condition)
Number of subjects: 9
Study 3544648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg, intramuscular injection)
Number of subjects: 85
Study 3544648 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg, intramuscular injection)
Number of subjects: 85
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 μg/strain QVLP vaccine
Number of subjects: 0
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg/strain QVLP vaccine
Number of subjects: 0
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg/strain QVLP vaccine
Number of subjects: 0
Study 31166987 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 or 15 μg/strain QVLP vaccine with alum
Number of subjects: 0
Study 31166987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29785686 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing group (informed that dizziness is a sign that the drug had started to work)
Number of subjects: 80
Study 29785686 — intervention group
Group type: COMPARATOR
Intervention: Neutral framing group (informed that dizziness is an unpleasant but well-known side effect)
Number of subjects: 80
Study 26567961 — intervention group
Group type: EXPERIMENTAL
Intervention: Arms positioned in the superior direction (Group A)
Number of subjects: 100
Study 26567961 — intervention group
Group type: COMPARATOR
Intervention: Arms positioned in the ventral direction (Group B)
Number of subjects: 100
Study 25363175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times a day)
Number of subjects: 90
Study 25363175 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (10 mg every other week for up to 12 sessions)
Number of subjects: 90
Study 25363175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pentoxifylline and Verapamil)
Number of subjects: 90
Study 22610179 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation without a noninvasive mechanical ventilation algorithm (PSV-NIV-)
Number of subjects: 17
Study 22610179 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation with a noninvasive mechanical ventilation algorithm (PSV-NIV+)
Number of subjects: 17
Study 22610179 — intervention group
Group type: COMPARATOR
Intervention: Neurally adjusted ventilatory assist without a noninvasive mechanical ventilation algorithm (NAVA-NIV-)
Number of subjects: 17
Study 22610179 — intervention group
Group type: COMPARATOR
Intervention: Neurally adjusted ventilatory assist with a noninvasive mechanical ventilation algorithm (NAVA-NIV+)
Number of subjects: 17
Study 20609718 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic FOCUS Shear (group A)
Number of subjects: 62
Study 20609718 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation and clamp-and-tie technique (group B)
Number of subjects: 62
Study 18562719 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic perfusion for ischemic segments
Number of subjects: 34
Study 18562719 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between systolic perfusion and diastolic perfusion in ischemic segments
Number of subjects: 34
Study 18562719 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic perfusion
Number of subjects: 34
Study 15987536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily for 10 days
Number of subjects: 42
Study 15987536 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 42
Study 15987536 — intervention group
Group type: COMPARATOR
Intervention: Control (no enoxaparin)
Number of subjects: 42
Study 12494614 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 6944 (small-surfaced, steroid-eluting electrode tip)
Number of subjects: 34
Study 12494614 — intervention group
Group type: COMPARATOR
Intervention: Model 6942 (conventional sized, steroid-eluting electrode tip)
Number of subjects: 34
Study 12494614 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 6944
Number of subjects: 34
Study 12494614 — intervention group
Group type: COMPARATOR
Intervention: Model 6942
Number of subjects: 34
Study 9475275 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg)
Number of subjects: 10
Study 9475275 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion (2.5 ng/kg/min)
Number of subjects: 10
Study 9475275 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (50 mg) pretreatment
Number of subjects: 10
Study 7644839 — intervention group
Group type: EXPERIMENTAL
Intervention: BW0%
Number of subjects: 120
Study 7644839 — intervention group
Group type: EXPERIMENTAL
Intervention: BW10%
Number of subjects: 120
Study 7644839 — intervention group
Group type: EXPERIMENTAL
Intervention: Shrinking‐BW
Number of subjects: 120
Study 7644839 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanding‐BW
Number of subjects: 120
Study 7644839 — intervention group
Group type: COMPARATOR
Intervention: no‐KR retention condition
Number of subjects: 120
Study 7644839 — intervention group
Group type: EXPERIMENTAL
Intervention: KR retention condition
Number of subjects: 120
Study 2562095 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of a local anesthetic solution containing 0.5% bupivacaine and 0.15 mEq of NaHCO3 (Group I)
Number of subjects: 40
Study 2562095 — intervention group
Group type: COMPARATOR
Intervention: 15 ml of a standard solution of 0.5% bupivacaine (Group II)
Number of subjects: 40
Study 801352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (LDH)
Number of subjects: 632
Study 801352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 632
Study 801352 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of LDH and DHE
Number of subjects: 632
Study 801352 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 632
Study 801352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups (LDH and DHE)
Number of subjects: 632
Study 31379213 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye shampoo with tea tree oil
Number of subjects: 62
Study 31379213 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears, topical steroids, and eye shampoos without tea tree oil (Control)
Number of subjects: 62
Study 30534990 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient portal
Number of subjects: 426
Study 30534990 — intervention group
Group type: COMPARATOR
Intervention: Tablet-only
Number of subjects: 426
Study 30534990 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 426
Study 28678120 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement (CL‐Deb)
Number of subjects: 190
Study 28678120 — intervention group
Group type: COMPARATOR
Intervention: Observation (CL‐noDeb)
Number of subjects: 190
Study 25616598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not explicitly mentioned; the focus is on the practice of testing for baseline differences in randomized controlled trials.
Number of subjects: 0
Study 23220013 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. busulfan at a dose of 11.2 mg/kg/d
Number of subjects: 80
Study 23220013 — intervention group
Group type: COMPARATOR
Intervention: other doses of busulfan
Number of subjects: 80
Study 21788312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% N(2)O
Number of subjects: 25
Study 21788312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% N(2)O
Number of subjects: 25
Study 21788312 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% N(2)O
Number of subjects: 25
Study 19920000 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily school exercise lessons for 1 year
Number of subjects: 182
Study 19920000 — intervention group
Group type: COMPARATOR
Intervention: Regular school sports twice weekly
Number of subjects: 182
Study 16753973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NIV (8 cm H2O inspiratory and 4 cm H2O expiratory pressure)
Number of subjects: 40
Study 16753973 — intervention group
Group type: COMPARATOR
Intervention: Sham NIV (<1 cm H2O continuous positive airway pressure)
Number of subjects: 40
Study 16753973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Active NIV and Sham NIV)
Number of subjects: 40
Study 15300074 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) with hemodilution therapy
Number of subjects: 20
Study 15300074 — intervention group
Group type: COMPARATOR
Intervention: Regular hemodilution therapy only
Number of subjects: 20
Study 15300074 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EECP and control) after 48 hours
Number of subjects: 20
Study 11561228 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 7
Study 11561228 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg valsartan
Number of subjects: 7
Study 11561228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9990360 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment for 4 and 7 days
Number of subjects: 0
Study 9990360 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol treatment
Number of subjects: 0
Study 9990360 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study 8090631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment of hyperthyroidism (0.81 GBq)
Number of subjects: 40
Study 8090631 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous treatment of differentiated thyroid cancer (1.85 GBq)
Number of subjects: 40
Study 8090631 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment of hyperthyroidism (0.81 GBq)
Number of subjects: 40
Study 8090631 — intervention group
Group type: COMPARATOR
Intervention: Oral treatment of differentiated thyroid cancer (1.85 GBq)
Number of subjects: 40
Study 3056057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 246
Study 3056057 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine, prednisone, and antilymphocyte globulin
Number of subjects: 246
Study 3056057 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely hyperuricemic patients (all on cyclosporine and prednisone)
Number of subjects: 246
Study 30744610 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended low-intensity psychological intervention using information and communication technologies (ICTs) combined with improved usual care.
Number of subjects: 300
Study 30744610 — intervention group
Group type: COMPARATOR
Intervention: Improved treatment as usual (control group).
Number of subjects: 300
Study 29582888 — intervention group
Group type: EXPERIMENTAL
Intervention: 25OHD (10 μg/day)
Number of subjects: 252
Study 29582888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 26647154 — intervention group
Group type: EXPERIMENTAL
Intervention: School meals
Number of subjects: 530
Study 26647154 — intervention group
Group type: COMPARATOR
Intervention: Lunch from home
Number of subjects: 530
Study 25249652 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM ER 15 mg/92 mg (15/92)
Number of subjects: 518
Study 25249652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 22830622 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise + Auricular acupressure (n=14)
Number of subjects: 21
Study 22830622 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi exercise (n=7)
Number of subjects: 21
Study 18712575 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomic gastric bypass with omentectomy
Number of subjects: 70
Study 18712575 — intervention group
Group type: COMPARATOR
Intervention: Laparotomic gastric bypass without omentectomy
Number of subjects: 70
Study 17985826 — intervention group
Group type: EXPERIMENTAL
Intervention: High-linoleate sunflower seed oil
Number of subjects: 405
Study 17985826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Original Emollient Ointment
Number of subjects: 405
Study 17985826 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 405
Study 16131946 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pharmacotherapy and psychotherapy)
Number of subjects: 0
Study 12035990 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Toric (Ciba Vision)
Number of subjects: 14
Study 12035990 — intervention group
Group type: EXPERIMENTAL
Intervention: FreshLook Toric (Wesley lessen)
Number of subjects: 14
Study 12035990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Toric (Vistakon)
Number of subjects: 14
Study 10101736 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 2 mg
Number of subjects: 0
Study 10101736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7594099 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (specific agent not mentioned); administered during menstruation.
Number of subjects: 12
Study 2178930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN)
Number of subjects: 360
Study 2178930 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 360
Study 2178930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) with heart failure
Number of subjects: 360
Study 2178930 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) with heart failure
Number of subjects: 360
Study 2178930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide 5-mononitrate (ISMN) without heart failure
Number of subjects: 360
Study 2178930 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) without heart failure
Number of subjects: 360
Study 378053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid aerosol (beclomethasone dipropionate)
Number of subjects: 34
Study 378053 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment)
Number of subjects: 34
Study 6925576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (oral)
Number of subjects: 4
Study 6925576 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study 29081307 — intervention group
Group type: EXPERIMENTAL
Intervention: vortioxetine 5 mg for 8 weeks
Number of subjects: 301
Study 29081307 — intervention group
Group type: EXPERIMENTAL
Intervention: vortioxetine 5 or 10 mg for 20 weeks, then randomized to vortioxetine or placebo for at least 24 weeks
Number of subjects: 301
Study 29081307 — intervention group
Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 301
Study 29081307 — intervention group
Group type: COMPARATOR
Intervention: placebo after 20 weeks of vortioxetine treatment
Number of subjects: 301
Study 29461913 — intervention group
Group type: EXPERIMENTAL
Intervention: TetIV
Number of subjects: 350
Study 29461913 — intervention group
Group type: COMPARATOR
Intervention: TriIV
Number of subjects: 350
Study 29461913 — intervention group
Group type: EXPERIMENTAL
Intervention: TetIV and TriIV
Number of subjects: 350
Study 27993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise prescription (ventilatory thresholds)
Number of subjects: 0
Study 27993169 — intervention group
Group type: COMPARATOR
Intervention: Standardized exercise prescription (HRR)
Number of subjects: 0
Study 27993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized and standardized exercise prescriptions
Number of subjects: 0
Study 27993169 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified exercise prescription for non-responders
Number of subjects: 0
Study 25366684 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus two APN telephone counseling sessions (n = 238)
Number of subjects: 472
Study 25366684 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 234)
Number of subjects: 472
Study 25366684 — intervention group
Group type: EXPERIMENTAL
Intervention: APN counseling
Number of subjects: 472
Study 22487270 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D locking titanium miniplates
Number of subjects: 10
Study 22487270 — intervention group
Group type: COMPARATOR
Intervention: Standard miniplate fixation
Number of subjects: 10
Study 19194342 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort extract (900 mg TID)
Number of subjects: 47
Study 17485023 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (n = 30)
Number of subjects: 53
Study 17485023 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (Control group, n = 21)
Number of subjects: 53
Study 15240578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 363